Therapeutic Area: Pediatrics ¦ Vaccine
21-Valent Pneumococcal Conjugate Vaccine
We are conducting a clinical trial to evaluate the 21-valent pneumococcal conjugate vaccine (PCV21), designed to protect against more strains of Streptococcus pneumoniae than current vaccines. Participants receive access to the investigational vaccine and comprehensive study-related care at no cost, while helping advance research that could strengthen community protection against serious pneumococcal disease.